Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | CCNE1 | P24864 | 8/20 | 0.37 |
| ▸ | CDK2 | P24941 | 8/20 | 0.37 |
| ▸ | KCNN3 | Q9UGI6 | 3/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
| ▸ | BMI1 | P35226 | 1/20 | 0.35 |
| ▸ | KCNJ6 | P48051 | 1/20 | 0.34 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.34 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | AGPAT2 | O15120 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19690905 | 0.86 | POLB (0.57) | POLBCCNE1CDK2KCNN3MAPT | |
| SCHEMBL19691006 | 0.81 | CCNE1 (0.48) | CCNE1CDK2MAPTMEN1NPC1 | |
| SCHEMBL19690992 | 0.80 | NPC1 (0.41) | PDE10ASMN1; SMN2NPC1ALDH1A1RAB9A | |
| SCHEMBL19690851 | 0.77 | IDH1 (0.44) | POLBCCNE1CDK2KCNN3ALOX5 | |
| SCHEMBL19690895 | 0.76 | POLB (0.45) | POLBCCNE1CDK2KCNN3ALOX5 | |
| SCHEMBL21144351 | 0.76 | IDH1 (0.47) | — | |
| SCHEMBL31127241 | 0.76 | IDH1 (0.47) | — | |
| SCHEMBL19708733 | 0.72 | POLB (0.38) | POLBCCNE1CDK2KCNN3ALOX5 | |
| SCHEMBL19690868 | 0.72 | ALDH1A1 (0.45) | POLBKCNN3MAPTSMN1; SMN2MEN1 | |
| SCHEMBL4880624 | 0.68 | TXN (0.53) | POLBALOX5PPARGMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170355708-A1 | POTASSIUM CHANNEL MODULATORS | CADENT THERAPEUTICS, INC. | 2017-12-14 | — | — | US | disclosed |
| US-20170355708-A1 | POTASSIUM CHANNEL MODULATORS | CADENT THERAPEUTICS, INC. | 2017-12-14 | — | — | US | disclosed |
| US-20170355708-A1 | POTASSIUM CHANNEL MODULATORS | CADENT THERAPEUTICS, INC. | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355708-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | POLB 4779/4885CCNE1 4852/4885CDK2 4182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.